Navigation Links
Development of Radioligand Binding Assays for the Motilin Receptor Using ScreenReady Targets.

fly, 12.5 μl of binding buffer without (total binding determination) or with motilin at 1 μM final concentration (non-specific binding determination) were first added to membrane-coated FlashPlate microplates, followed by the addition of 12.5 μl [125I]-motilin. Incubation was performed at room temperature for 1 to 5 hours before counting on a PerkinElmer TopCount instrument (30 seconds/well).

Kd and Ki values were calculated using GraphPad Prism Software. Signal to background ratio (S/B) (total values/ nonspecific values) was calculated using a concentration of radioligand close to the Kd value.

Results and Discussion

Saturation Binding Assays
Membranes from CHO cells expressing the human motilin MTL-R1A receptor were immobilized into 96-well FlashPlate microplates and the affinity of [125I]-motilin for the receptor was determined. Saturation experiments using motilin ScreenReady Targets were performed on the day of membrane immobilization (Figure 2, A) or upon storage at 4C for three months (Figure 2, B). A similar single class of high affinity binding sites was detected from the saturation experiment performed on the day of membrane immobilization or after three months upon storage at 4C (Kd = 1.0 nM and 0.75 nM, respectively). Calculated Kd values were comparable to those previously reported (Feighner et al ., 1999; Thielemans et al ., 2001). Bmax values were also very similar in both assays (4.3 pmol/mg at t= 0 and 3.6 pmol/mg at t= 3 months). S/B values calculated at a concentration of radioligand close to the Kd value were comparable in both assays (5.1 vs. 4.6), showing that the immobilized motilin receptor maintained its pharmacological binding properties for at least three months at 4C.

<
'"/>

Source:


Page: All 1 2 3 4 5

Related biology technology :

1. The let-7 microRNA Family Regulates RAS: Implications for Development and Oncogenesis
2. Rapid Method Development With the BioLogic DuoFlow Chromatography System for the Purification of His-Tagged Proteins
3. A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis
4. Development of a Multiplex Bead-Based Assay for Antibody Screening of a Nonhuman Primate Colony on the Bio-Plex System
5. Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System
6. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
7. Development of an NK2 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System
8. Development of an adrenergic α2a receptor binding assay using the LEADseeker Multimodality Imaging System
9. Development of a CRF1 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System
10. Purification of the Components of Human Macular Carotenoid-Binding Complex, Rev A
11. Use of FlashPlate Technology for In Vitro Measurement of [35S]-GTPγS Binding in CHO Cells Expressing the Human 5-HT1B Receptor
Post Your Comments:
(Date:7/30/2015)... Marshall, MN (PRWEB) , ... July 31, 2015 , ... ... Ralco Enrichment Center at the Lyon County Fair to be held August 5-9 in ... more about where their meals come from and how agriculture impacts their daily lives. ...
(Date:7/30/2015)... 30, 2015 According to a ... Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, ... Clinical Trial), by End Users - Global Forecast to ... to reach USD 2,107.99 million by 2020 from USD ... Browse more than 75 ...
(Date:7/30/2015)... 2015 Ascendis Pharma A/S (Nasdaq: ... innovative TransCon technology to address significant unmet medical ... six-month Phase 2 study to evaluate the safety ... 53 treatment-naïve, pre-pubertal children with growth hormone deficiency, ... with the top-line results from our Phase 2 ...
(Date:7/29/2015)... Sanofi, a global and ... quarter of 2015. CEO Olivier Brandicourt ... in different businesses. Watch video interview ... Topics covered in the interview include:  ... Performance drivers - Diabetes ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... Reportlinker.com announces that a new ... its catalogue: DNA ... Purchase Plans and The Impact of ... http://www.reportlinker.com/p0681348/DNA-Microarray-Market-Trends-Installed-Base-Applications-Purchase-Plans-and-The-Impact-of-Next-Gen-Sequencing.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic DNA ...
... Novartis announced today new pivotal Phase III data showing ... (SJIA) were able to substantially reduce their use of ... of commencing treatment with ACZ885 (canakinumab) (p<0.0001)[1]. ... primary endpoints, will be presented on November 9th at ...
... Jennerex, Inc., a private clinical-stage biotherapeutics company focused ... oncolytic products for cancer, today presented final data from ... in patients with advanced liver cancer showing a statistically ... dose group versus the low dose group.  The final ...
Cached Biology Technology:DNA Microarray Market Trends (Installed Base, Applications, Purchase Plans and the Impact of Next-Gen Sequencing) 2DNA Microarray Market Trends (Installed Base, Applications, Purchase Plans and the Impact of Next-Gen Sequencing) 3DNA Microarray Market Trends (Installed Base, Applications, Purchase Plans and the Impact of Next-Gen Sequencing) 4DNA Microarray Market Trends (Installed Base, Applications, Purchase Plans and the Impact of Next-Gen Sequencing) 5DNA Microarray Market Trends (Installed Base, Applications, Purchase Plans and the Impact of Next-Gen Sequencing) 6DNA Microarray Market Trends (Installed Base, Applications, Purchase Plans and the Impact of Next-Gen Sequencing) 7DNA Microarray Market Trends (Installed Base, Applications, Purchase Plans and the Impact of Next-Gen Sequencing) 8DNA Microarray Market Trends (Installed Base, Applications, Purchase Plans and the Impact of Next-Gen Sequencing) 9Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 2Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 3Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 4Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 5Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 6Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 7Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 2Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 3Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 4Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 5Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 6
(Date:7/31/2015)... , 31 de julho de 2015 A ... www.icg-10.org ) será realizada pela BGI de 22-25 de outubro ... A conferência está celebrando seu 10 o. ... a ICG se tornou uma das reuniões mais influentes ... encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
(Date:7/31/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT METHOD AND ... advance crypto-currencies such as Bitcoin into the consumer market ... to manage all payments.  The technology ...
(Date:7/27/2015)... , July 27, 2015   Zynx Health ... experience-based clinical improvement solutions, today announced that its ... now available on Android smartphones and tablets. With ... post-care organizations can use ZynxCarebook to securely exchange ... condition, streamline care transitions to other care settings, ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... VIB and Ghent University, both in Flanders, Belgium, is ... worth 750 000 euro. The Krber Foundation annually awards ... Friml gets the prize for his research into the ... the genetic, molecular and cellular processes that direct the ...
... have discovered components of the bovine mastitis-causing bacterium, Streptococcus ... This discovery could lead the way to finally developing a ... nearly 200M per year, requires the large scale use of ... A solution to this problem will be an important contribution ...
... the world,s largest living reptile - the estuarine crocodile - ... by huge stretches of ocean despite being a poor swimmer ... ecologists. Publishing their new study in the British Ecological Society,s ... a surfer catching a wave, the crocodiles ride ocean currents ...
Cached Biology News:VIB-UGent scientist Jiri Friml receives Koerber European Science Award 2010 2New discovery could aid development of elusive bovine mastitis vaccine 2Crocodiles ride ocean currents for ocean travel 2Crocodiles ride ocean currents for ocean travel 3
... silencing experiments often call for critical, ... Transfection Agent refines siRNA transfection protocols ... lipid-based formulation can be used to ... are subcultured without increased cytotoxicity. ...
... The CHEMICON® CaspaTag™ Pan-Caspase In Situ ... detection of active caspases in cells undergoing ... only. Not for use in diagnostic or ... Assay Kits use a novel approach to ...
... INTERFERin is a new-generation siRNA transfection ... efficiency at 1 nM siRNA in a ... with excellent cell viability. Using low siRNA ... effects observed when transfecting siRNA at higher ...
... Cell and Tissue Staining Kits are intended ... range of histological and cytological specimens. These ... antibodies manufactured by either R&D Systems or ... on the formation of the Avidin-Biotin Complex ...
Biology Products: